Send to

Choose Destination
Oncotarget. 2017 Nov 27;8(69):113766-113791. doi: 10.18632/oncotarget.22667. eCollection 2017 Dec 26.

BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas.

Huang SP1,2,3, Chang YC3, Low QH4, Wu ATH5, Chen CL1,6,7, Lin YF1, Hsiao M3,5,8.

Author information

Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Department of Neurology, PoJen General Hospital, Taipei, Taiwan.
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.
Department of Pathology, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan.
Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.


There is variation in the survival and therapeutic outcome of patients with glioblastomas (GBMs). Therapy resistance is an important challenge in the treatment of GBM patients. The aim of this study was to identify Temozolomide (TMZ) related genes and confirm their clinical relevance. The TMZ-related genes were discovered by analysis of the gene-expression profiling in our cell-based microarray. Their clinical relevance was verified by in silico meta-analysis of the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) datasets. Our results demonstrated that BICD1 expression could predict both prognosis and response to therapy in GBM patients. First, high BICD1 expression was correlated with poor prognosis in the TCGA GBM cohort (n=523) and in the CGGA glioma cohort (n=220). Second, high BICD1 expression predicted poor outcome in patients with TMZ treatment (n=301) and radiation therapy (n=405). Third, multivariable Cox regression analysis confirmed BICD1 expression as an independent factor affecting the prognosis and therapeutic response of TMZ and radiation in GBM patients. Additionally, age, MGMT and BICD1 expression were combinedly utilized to stratify GBM patients into more distinct risk groups, which may provide better outcome assessment. Finally, we observed a strong correlation between BICD1 expression and epithelial-mesenchymal transition (EMT) in GBMs, and proposed a possible mechanism of BICD1-associated survival or therapeutic resistance in GBMs accordingly. In conclusion, our study suggests that high BICD1 expression may result in worse prognosis and could be a predictor of poor response to TMZ and radiation therapies in GBM patients.


BICD1; MGMT; biomarker; glioblastoma (GBM); temozolomide (TMZ)

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center